Ofatumumab Interruption Results in Disease Reactivation: A Case Report

Read full text Summarise with VIRAT
Authors: Jeffrey Hernandez, Silvia R. Delgado
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Multiple sclerosis (MS) specialists are increasingly using highly effective anti-CD20 therapies to quickly and successfully achieve disease control. We present the case of a 30-year-old Black woman with relapsing MS who did well on ofatumumab for several years before her treatment was interrupted, leading to a relapse 4 months later. Her symptoms improved with intravenous steroid treatment. After restarting ofatumumab, she remained clinically and radiologically stable. To our knowledge, this is the first case report on disease activity following the interruption of ofatumumab in a person with MS. Our case highlights a real-world clinical scenario that may have clinical implications for people with MS treated with ofatumumab, an anti-CD20 therapy with a shorter half-life, after stopping treatment or attempting to become pregnant.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Polyomavirus and related diseases Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
International Journal of MS Care
Volume
28
Issue
2
Pages
101–101
Publication date
26 March 2026
Language
EN